The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Hyponatremia in Hospitalized Cancer Patients and Its Impact on Clinical Outcomes
Open accessAbstract
BACKGROUND Hyponatremia is the most common electrolyte abnormality in clinical practice, yet little is known about its frequency in patients with cancer or its impact on their clinical outcomes. STUDY DESIGN Retrospective analysis of prospectively collected data. SETTING & PARTICIPANTS Patients with cancer admitted to the University of Texas M.D. Anderson Cancer Center in 2006 for 3 months. PREDICTOR Serum sodium levels categorized as eunatremia (serum sodium, 135-147 mEq/L) and mild (134-130 mEq/L), moderate (129-120 mEq/L), and severe (<120 mEq/L) hyponatremia. OUTCOMES (1) Length of hospital stay and (2) 90-day mortality. RESULTS In 4,702 admissions in 3,357 patients with cancer, hyponatremia (serum sodium <135 mEq/L) was noted in 47% of admissions. It was mild in 36%, moderate in 10%, and severe in 1%. Hyponatremia was acquired during the hospital stay in 24%. Using the first admission data, mean length of stay was 5.6 ± 5.0 days for patients with eunatremia and 9.9 ± 9.2, 13.0 ± 14.1, and 11.5 ± 12.6 days for those with mild, moderate, and severe hyponatremia, respectively. The respective HRs in the multivariate Cox model for longer hospital stay, using patients with eunatremia as reference, were 1.92 (95% CI, 1.75-2.13; P < 0.01), 2.94 (95% CI, 2.56-3.45; P < 0.01), and 2.32 (95% CI, 1.32-4.00; P = 0.01). 283 (8.4%) deaths occurred during 90 days, and in the multivariate model, the respective HRs for 90-day mortality for mild, moderate, and severe hyponatremia were 2.04 (95% CI, 1.42-2.91; P < 0.01); 4.74 (95% CI, 3.21-7.01; P < 0.01), and 3.46 (95% CI, 1.05-11.44; P = 0.04). These findings were consistent when analyses were repeated with sodium levels in tertiles. LIMITATIONS Observational study, retrospective, inability to adjust for all comorbid conditions. CONCLUSION Hyponatremia in patients with cancer is associated with longer hospital stay and higher mortality. Whether long-term correction of hyponatremia would improve these outcomes remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Cited by
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E., Ichai, C., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3210-2 · Cited by 1,020
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E. J., Ichai, C., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1020 · Cited by 855
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E. J., Ichai, C., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu040 · Cited by 579
Prevalence of Hyponatremia and Association with Mortality: Results from NHANES
Mohan, S., Gu, S., Parikh, A., & Radhakrishnan, J. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.07.021 · Cited by 261
Gadelha, M. R., Wildemberg, L. E., & Kasuki, L. (2022) · The Pituitary · doi:10.1016/b978-0-323-99899-4.00003-2 · Cited by 2
Metadata
- Authors
- Doshi, S. M., Shah, P., Lei, X., Lahoti, A., & Salahudeen, A. K.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 59
- Issue
- 2
- Pages
- 222-228
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2101794210
- Cited by
- 218
- References
- 1
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.